2.50
Hdl Handle:
http://hdl.handle.net/10541/77932
Title:
The place of pegvisomant in the acromegaly treatment algorithm.
Authors:
Paisley, Angela N; Trainer, Peter J; Drake, William M
Abstract:
The disfiguring disease acromegaly results from hypersecretion of growth hormone (GH). The main goals of treatment for acromegaly include normalisation of biochemical markers of disease activity to restore normal life expectancy, amelioration of signs and symptoms of the disease, removal of the pituitary tumour without damaging the optic chiasm and other peripituitary structures, and preservation of pituitary function. Conventional options for treatment of acromegaly include surgery, radiotherapy (RT), and medical therapy with either dopamine agonists or somatostatin (SMS) analogues. The advent of the genetically engineered growth hormone analogue pegvisomant is unlikely to alter significantly the place of surgery and RT in the treatment algorithm for acromegaly biochemical control as determined based on serum IGF-I concentrations is achievable with pegvisomant in virtually all patients, and it will clearly become the drug of choice in patients partially or completely unresponsive to SMS analogues. Preliminary studies suggest improved insulin sensitivity for a given IGF-I with pegvisomant compared with SMS analogues; if these results are confirmed by results of future studies, such a metabolic advantage may encourage the use of pegvisomant.
Affiliation:
Department of Endocrinology, Christie Hospital, Manchester, UK.
Citation:
The place of pegvisomant in the acromegaly treatment algorithm. 2004, 14 Suppl A:S101-6 Growth Horm. IGF Res.
Journal:
Growth Hormone & IGF Research
Issue Date:
Jun-2004
URI:
http://hdl.handle.net/10541/77932
DOI:
10.1016/j.ghir.2004.03.039
PubMed ID:
15135788
Type:
Article
Language:
en
ISSN:
1096-6374
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPaisley, Angela N-
dc.contributor.authorTrainer, Peter J-
dc.contributor.authorDrake, William M-
dc.date.accessioned2009-08-19T16:24:10Z-
dc.date.available2009-08-19T16:24:10Z-
dc.date.issued2004-06-
dc.identifier.citationThe place of pegvisomant in the acromegaly treatment algorithm. 2004, 14 Suppl A:S101-6 Growth Horm. IGF Res.en
dc.identifier.issn1096-6374-
dc.identifier.pmid15135788-
dc.identifier.doi10.1016/j.ghir.2004.03.039-
dc.identifier.urihttp://hdl.handle.net/10541/77932-
dc.description.abstractThe disfiguring disease acromegaly results from hypersecretion of growth hormone (GH). The main goals of treatment for acromegaly include normalisation of biochemical markers of disease activity to restore normal life expectancy, amelioration of signs and symptoms of the disease, removal of the pituitary tumour without damaging the optic chiasm and other peripituitary structures, and preservation of pituitary function. Conventional options for treatment of acromegaly include surgery, radiotherapy (RT), and medical therapy with either dopamine agonists or somatostatin (SMS) analogues. The advent of the genetically engineered growth hormone analogue pegvisomant is unlikely to alter significantly the place of surgery and RT in the treatment algorithm for acromegaly biochemical control as determined based on serum IGF-I concentrations is achievable with pegvisomant in virtually all patients, and it will clearly become the drug of choice in patients partially or completely unresponsive to SMS analogues. Preliminary studies suggest improved insulin sensitivity for a given IGF-I with pegvisomant compared with SMS analogues; if these results are confirmed by results of future studies, such a metabolic advantage may encourage the use of pegvisomant.en
dc.language.isoenen
dc.subjectPituitary Canceren
dc.subject.meshAcromegaly-
dc.subject.meshDopamine Agonists-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshPituitary Neoplasms-
dc.subject.meshSomatostatin-
dc.titleThe place of pegvisomant in the acromegaly treatment algorithm.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Manchester, UK.en
dc.identifier.journalGrowth Hormone & IGF Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.